sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6–8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." ;
    prov:wasQuotedFrom pubmed:17554333 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:17554333 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}